Betamethasone Dipropionate (CAS 5593-20-4)
QUICK LINKS
Betamethasone dipropionate is a compound extensively studied in fields such as biochemistry and molecular biology. It is used in research focused on the molecular pathways of inflammation and immune response, where it serves as a tool to understand glucocorticoid receptor activation and the subsequent transcriptional regulation of target genes. In cell culture studies, betamethasone dipropionate is applied to investigate the anti-inflammatory mechanisms at a cellular level, providing insight into the modulation of cytokine production and the inhibition of inflammatory mediators. Additionally, this compound is used in dermatological research to study the processes involved in skin homeostasis and disorders. In these applications, betamethasone dipropionate helps elucidate the effects of glucocorticoids on keratinocyte proliferation and differentiation. Furthermore, it is involved in the examination of glucocorticoid-induced skin atrophy, aiming to understand the underlying molecular changes that occur in the extracellular matrix components of the dermis.
Betamethasone Dipropionate (CAS 5593-20-4) References
- Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. | Charakida, A., et al. 2006. Expert Opin Pharmacother. 7: 597-606. PMID: 16553575
- Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. | McCormack, PL. 2011. Drugs. 71: 709-30. PMID: 21504248
- Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp. | McCormack, PL. 2011. Am J Clin Dermatol. 12: 421-4. PMID: 21967117
- Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review. | Yan, R., et al. 2016. Indian J Dermatol Venereol Leprol. 82: 135-44. PMID: 26924402
- Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. | Kin, KC., et al. 2016. Expert Rev Clin Pharmacol. 9: 789-97. PMID: 27089906
- DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. | Yamauchi, P. 2017. Expert Rev Clin Immunol. 13: 85-91. PMID: 27967262
- Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. | Patel, NU., et al. 2017. Clin Cosmet Investig Dermatol. 10: 385-391. PMID: 29033598
- Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. | Amat-Samaranch, V. and Puig, L. 2020. Expert Opin Drug Saf. 19: 423-432. PMID: 32243212
- Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. | Megna, M., et al. 2020. Expert Rev Clin Immunol. 16: 599-620. PMID: 32476507
- Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice. | Fabbrocini, G., et al. 2022. J Dermatolog Treat. 33: 2425-2432. PMID: 34694953
- Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment. | Rudnicka, L., et al. 2021. J Clin Med. 10: PMID: 34884291
- Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis. | Taylor, A., et al. 2023. Ann Pharmacother. 57: 341-347. PMID: 35730211
- Betamethasone Dipropionate Nanocrystals: Investigation, Feasibility and In Vitro Evaluation. | Patel, V. and Mehta, TA. 2022. AAPS PharmSciTech. 23: 197. PMID: 35835936
- Betamethasone Dipropionate Derivatization, Biotransformation, Molecular Docking, and ADME Analysis as Glucocorticoid Receptor. | Rashid, S., et al. 2022. Biomed Res Int. 2022: 6865472. PMID: 35865666
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Betamethasone Dipropionate, 1 g | sc-210912 | 1 g | $198.00 |